A competitive antagonist peptide (LSKL) targets TSP-1’s interaction site with latent TGF-β1 and also attenuates fibrosis in a mouse model of toxin induced liver fibrosis [16] and subarachnoid fibrosis [17]. Here, THBS1 is linked to Hepatic fibrosis.